X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.393 0.0036 (0.92%) Market Cap: 67.03 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 30/100

X4 Pharmaceuticals Inc To Discuss Key Top-Line 4WHIM Trial Results Transcript

Nov 29, 2022 / 09:30PM GMT
Release Date Price: $1.85 (+5.11%)
Operator

Greetings and welcome to the X4 Pharmaceuticals conference call to discuss the positive results of its Phase 3 clinical trial in WHIM syndrome. (Operator Instructions) As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.

Dan Ferry
LifeSci Advisors - IR

Thank you, operator, and good afternoon, everyone. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in X4's most recent filings with the SEC, including the third-quarter 2022 10-Q, which was filed on November 3.

Presenting on today's call will be X4's President and Chief Executive Officer, Dr. Paula Ragan, and the company's Interim Chief Medical Officer, Dr. Murray Stewart. Following prepared remarks, we will open the call to your questions and will be joined by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot